Biotech company developing precision epigenome editing for programmable gene expression, spun out of EMBL.
| Date | Round | Amount |
|---|---|---|
| Jun 2026 | Pre Seed Epitome Therapeutics closed an oversubscribed pre-seed equity round to advance its CADENCE epigenome editing platform and expand its team. | $2.3M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.